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Background/Aims : Behcet's disease (BD) is a systemic disorder associated with a characteristic vasculitis that can 
involve  both  veins  and  arteries  of  all  sizes.  Endothelial  activation or injury is a characteristic feature of BD. Endothelial 
dysfunction  is  widely  regarded  as  being  the  initial  lesion  in  the  development  of  atherosclerosis.  The  carotid  artery 
intima-media  thickness  (IMT)  is  a  widely  accepted  marker  of  subclinical  atherosclerosis.  We  aimed  to  determine  the 
carotid  IMT  in  BD  patients  with  using  high-resolution  B-mode  Doppler  ultrasonography. 
Methods : We studied 40 patients (24 males, mean age: 39.1±8.5 years) who were diagnosed by the international 
diagnostic  criteria  of  Behcet's  disease  and  20  healthy  controls  (13  males,  mean  age:  40.2±5.1  years),  and  the  two 
groups  were  matched  by  age  and  gender.  No  subject  in  either  grou p  h a d  a  h i s t o r y  o f  a t h e r o s c l e r o s i s  o r  i t s  
complications. The clinical data, including the age of onset, the duration of disease, a history of medication, the activity 
score  and  the  laboratory  data  were  analyzed. 
Results  : T h e  c a r o t i d  I MT  i n  t h e  B D  g r o u p  w a s  s i g n i f i c a n t l y  h i g h e r  t h a n  that  in  the  control  group  (0.71±0.22  mm 
vs. 0.59±0.09 mm, respectively, p<0.01). Cardiac and major vessel involvements were not identified in the BD group. 
However,  minor  vascular  involvements  were  documented  in  2  patien t s  w i t h  d e e p  v e i n  t h r o m b o s i s ,  i n  4  p a t i e n t s  w i t h  
superficial thrombophlebitis and in 2 patients with pseudoaneurysm. The carotid IMT in the patients with posterior uveitis 
or  retinal  vasculitis  was  higher  than  that  of  the  patients  without  these  findings  (0.85±0.21  mm  vs.  0.64±0.10  mm, 
respectively,  p=0.007),  but  there  was  no  difference  of  the  IMT  according  to  minor  vascular  involvement. 
Conclusions : Despite that there was no significant cardiovascular involvement in the BD patients, the carotid IMT was 
significantly  higher  in  the  BD  patients  as  compared  with  the  healthy  controls.
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INTRODUCTION 
Behcet's  disease  (BD)  is  a  chronic,  relapsing,  multisystemic 
inflammatory  disease  that's  characterized  by  recurrent  oral  and 
genital  ulceration  and  skin  and  ocular  lesions
1).  Cardiovascular 
involvement occurs in 7～31% of the BD patients
2,  3). There may 
be different types of vascular involvement, yet the majority of the 
v a s c u l a r  i n v o l v e m e n t  i s  i n  t h e  v e n o u s  s y s t e m  a n d  a r t e r i a l  
involvement  is  rare.  In  general,  BD  patients  with  major  vessel 
involvement  have  a  poor  prognosis. 
Chronic  inflammation  is  a  non-traditional  risk  factor  in  the 
pathogenesis of atherosclerosis
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has  previously  been  shown  in  inflammatory  rheumatic  disease 
s u c h  a s  r h e u m a t o i d  a r t h r i t i s  ( R A )  a n d  s y s t e m i c  l u p u s  e r y t h e -
matosus  (SLE)
5, 6).  Acute  systemic  inflammation  and  chronic 
systemic  vasculitis  are  associated  with  endothelial  cell 
dysfunction  (ECD)
7, 8). 
The histopathological features of BD are mainly characterized 
by vasculitis, with prominent neutrophil and monocyte infiltration 
in the perivascular regions with or without fibrin deposition in the 
vessel  walls
9).  Although  the  definite  pathogenic  mechanism  for 
the  vascular  lesions  in  BD  patients  remains  unclear,  endothelial 
dysfunction  is  thought  to  play  an  important  role  in  the 
development  of  these  lesions.  Histologic  evidence  of  vasculitis 
with endothelial cell activation or injury is a characteristics feature 
of  BD
10).  ECD  is  widely  regarded  as  the  initial  lesion  in 
atherogenesis
11)  and  recent  studies  have  shown  that  an 
increased  carotid  intima-media  thickness  (IMT)  was  significantly 
correlated  with  ECD
12). 
I n  t h i s  s t u d y ,  w e  i n v e s t i g a t e d  t h e  c a r o t i d  I M T  a n d  p l a q u e  
formation  in  BD  by  using  high-resolution  B-mode  ultrasono-
graphy.  We  evaluated  the  relationship  between  such  factors  as 
vascular  involvement,  other  severe  manifestations,  disease 
act i vi t y or t he us e of  i mmunosuppr essi ve agent  and t he carot i d 
I MT  i n  p a t i e n t s  w i t h  B D .
MATERIALS AND METHODS
Subjects
We  prospectively  analyzed  the  patients  who  visited  the 
Department  of  Rheumatology  at  Chonnam  National  University 
Hospital from July 2004 to October 2004 and from June 2005 
to October 2005, and these were the patients who were eligible 
for participation in this study. Forty consecutive patients with BD 
(mean  age:  39.1±8.5  years,  60%  males)  who  fulfilled  the 
International  Study  Group  Criteria
13)  were  finally  enrolled.
As  the  healthy  control  group,  20  age  and  gender-matched 
healthy  controls  (mean  age:  40.2±5.1  years,  male  65%)  were 
included.  We  excluded  those  subjects  with  hypertension, 
diabetes mellitus or a previous history of ischemic heart disease 
or cerebrovascular events. None of the subjects had a history of 
smoking  or  statin  therapy.
Clinical  assessments
We  collected  the  clinical  data  on  the  disease  duration,  the 
medication  history,  the  clinical  manifestation  and  the  disease 
activity score for BD at the time of study and during the month 
before  the  study.  The  disease  activity  score  was  calculated  by 
summing the points for all the disease manifestations as follows: 
1 point for each mild symptom (oral or genital ulcer, skin lesions, 
monoarticular  arthritis  and  superficial  thrombophlebitis);  2  points 
for  each  moderate  symptom  (arthritis,  small  or  medium-sized 
v e s s e l  i n v o l v e m e n t ,  a n t e r i o r  u v e i t i s  a n d  g a s t r o i n t e s t i n a l  
ulceration);  and  3  points  for  each  severe  disease  manifestation 
(posterior/pan  uveitis  or  retinal  vasculitis,  gastrointestinal 
ulceration with bleeding or perforation, major vessel involvement 
and  major  organ  involvement)  (Table  1)
14, 15). 
Laboratory  analysis
We  measured  the  laboratory  parameters  at  the  time  of  the 
ultrasound  scan.  The  erythrocyte  sedimentation  rate  (ESR)  was 
measured  by  using  the  modified  Westergren  method  and  the 
C-reactive protein (CRP) level was assessed by the turbidmetric 
immunoassay with using a Hitachi 7600 analyzer (Hitachi, Tokyo, 
Japan).  The  serum  levels  of  total  cholesterol,  triglyceride, 
h i g h - d e n s i t y  l i p o p r o t e i n  c h o l e s t e r o l  a n d  l o w - d e n s i t y  l i p o p r o t e i n 
cholesterol were measured by standard enzymatic methods. The 
lipoprotein  (a)  level  was  measured  by  nephelometry  and  the 
serum homocysteine level was measured by chemiluminescence 
immunoassay.
Carotid  artery  evaluation  by  B-mode  ultrasound
The  carotid  IMT  and  plaques  were  measured  in  the  left  and 
right  common  carotid  arteries  (CCA)  by  using  high-resolution 
B - m o d e  u l t r a s o u n d  ( H P  S o n o s - 5 5 0 0 ,  P h i l i p s ,  U S A )  w i t h  a n  
electric linear transducer (midfrequency 11.0 MHz). The left and 
right  CCAs  were  scanned  with  the  beam  focused  on  the  near 
and  far  walls  of  the  distal  2  cm  of  the  common  carotid  artery 
proximal  to  its  bifurcation.  The  IMT  was  measured,  at  3  points 
o n  t h e  f a r  w a l l s  o f  b o t h  d i s t a l  C C A s ,  a s  t h e  d i s t a n c e  f r o m t h e  
leading  edge  of  the  first  echogenic  line  to  the  leading  edge  of 
the  second  echogenic  line,  as  defined  by  Pignoli
16).  The  3  IMT 
points were 1) the site of the greatest thickness, 2) a point 1 cm 
upstream and 3) a point 1 cm downstream from the site of the 
greatest  thickness.  The  values  from  the  3  locations  were 
averaged  to  produce  a  mean  IMT  for  each  side.  Plaque  was 
d e f i n e d  e i t h e r  a s  a  d i s t i n c t  p r o t r u s i o n  o f  >  1 . 5  m m  i n t o  t h e  
vessel  lumen  or  as  definite  echogenicity  with  a  posterior 
echogenic  shadow
17).
Statistics
All  the  metric  variables  are  described  as  means±standard 
deviations.  The  differences  of  the  metric  variables  between  the 
groups  were  analyzed  using  t-tests  and  chi-square  statistics. 
Correlations  between  the  IMT  and  parameters  were  described 
with  Pearson's correlation  coefficients. All  the  statistical  process 
was done using SPSS-PC 11.0 (Statistical package for the social 
sciences,  SPSS-PC  Inc.  Chicago,  USA).  A  p  value  <0.05  was 
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Score Clinical  findings
 1
 2
 3
Oral  ulceration
Genital  ulceration
Skin  lesion:  Erythema  nodusum‐like  lesions, 
  Pseudofolliculitis/papulopustular  lesion
Monoartricular  arthtirits
Superficial  vein  thrombophlebitis
Arthritis  involving  two  joints  or  more
Gastrointestinal  ulceration  without  complications
Anterior  uveitis
Small  or  medium‐sized  vessel  involvement  not  related  to 
vital  organ
Posterior/pan  uveitis  or  retinal  vasculitis
Gastrointestinal  ulceration  with  bleeding  or  perforation
Major  vessel  involvement
Major  organ  involvement  such  as  brain,  lungs  or  heart
Table  1.  The  disease  activity  score  for  Behcet’s  disease
Figure 1. Carotid intima-media thickness in the patients with Behcet’s 
disease  and  the  healthy  controls  (p=0.006).
BD  patients  (n=40) Healthy  controls  (n=20) p v a l u e
Age  (years)
M a l e  ( n ,  % )
ESR  (mm/hr) 
CRP  (mg/dL) 
Total  cholesterol  (mg/dL)
Triglyceride  (mg/dL)
High-density  lipoprotein  cholesterol  (mg/dL)
Low-density  lipoprotein  cholesterol  (mg/dL)
Lipoprotein  (a)  (mg/dL)
Homocysteine  (umol/dL)
39.1±8.5
24  (60)
10.7±10.4
0.51±0.52
170.5±36.9
136.1±95.4
62.2±30.0
103.9±27.5
16.2±12.7
10.5±5.9
40.2±5.1
13  (65)
10.5±9.6
0.34±0.23
181.1±36.2
139.4±37.6
56.3±14.8
112.1±29.6
14.9±14.5
9.0±2.9
0.236
0.783
0.997
0.151
0.572
0.610
0.083
0.105
0.632
0.747
Table  2.  Baseline  clinical  characteristics
RESULTS
Clinical  and  laboratory  characteristics 
The clinical characteristics are listed in Table 2. No significant 
differences  of  age,  gender  and  the  lipid  profiles  were  observed 
b e t w e e n  t h e  g r o u p s .  T h e  m e a n  v a l u e s  o f  t h e  E S R ,  C R P  a n d  
lipid profiles were within the normal limits in both groups. There 
were no significant differences in the laboratory findings between 
the  groups. 
The clinical findings of BD are shown Table 3. The mean age 
at  the  time  of  diagnosis  was  32.5±11.5  years  and  the  mean 
disease duration was 5.2±4.0 years. Seventeen patients (42.5%) 
had severe manifestations; posterior uveitis or retinal vasculitis in 
10  patients,  ileocecal  ulcerations  with  bleeding  or  perforation i n  
4 patients and neuro-Behcet disease in 3 patients. However, any 
cardiac  involvement  and  major  vessel  involvement  were  not 
detected.  Twenty-four  patients  (60%)  received  immuno-
suppressive therapy with one or more drugs. Ten patients took 
high-dose  steroid,  10  took  cyclosporine,  3  took  cyclopho-
phamide  and  7  took  azathioprine.  The  disease  activity  score  at 
the  time  of  the  study  and  during  the  month  before  the  study 
were  0.7±0.3  and  1.3±1.3,  respectively.
IMT  and  the  clinical  and  laboratory  variables
The  carotid  IMT  in  the  BD  patients  was  positively  correlated 
with age (r=0.462, p=0.040), but it was  not correlated with the 
disease  duration,  the  cumulative  steroid  dose,  the  disease 
activity  score,  the  ESR,  the  CRP  level  and  the  lipid  profiles 
(Table  4).
IMT  of  the  CCAs
The  carotid  IMT  in  the  BD  patients  was  significantly  higher 
than that in the healthy controls (0.71±0.22 mm vs. 0.59±0.11 
mm,  respectively,  p=0.006)  (Figure  1).  Carotid  plaque  was 
present in 1 BD patient and in none of the controls. In the BD 
patient  group,  the  BD  patients  with  posterior  uveitis  or  retinal 
v a s c u l i t i s  h a d  a  s i g n i f i c a n t l y  h i g h e r  c a r o t i d  I M T  t h a n  t h o s e  
without  posterior  uveitis  or  retinal  vasculitis  (0.85±0.21  vs. 
0.64±0.10  mm,  respectively,  p=0.007)  (Table  5).  However,  no 
difference  of  the  carotid  IMT  in  the  patients  with  BD  was 
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  Values
Age  at  diagnosis  (years)
Disease  duration  (years)
General  manifestations  (n,  %)
    Oral  ulcerations
    Genital  ulcerations
  E r y t h e m a  n o d o s u m ‐like  lesions
    Pseudofolliculits/papulopustular  lesions
  O c u l a r  l e s i o n s
  P a t h e r g y  t e s t
  A r t h r i t i s
    Ileocecal  ulcertations
    Vascular  lesion
    D e e p  v e i n  t h r o m b o s i s
        Superficial  thrombophlebitis
    P s e u d o a n e u r y s m
Severe  manifestations  (n,  %)
    Posterior  uveitis  or  retinal  vasculitis
    Ileocecal  ulcerations  with  bleeding  or  perforation
    Major  organ  involvement  (central  nervous  system)
    Major  vessel  involvement
Disease  activity  score  for  Behcet’s  disease
    at  the  time  of  the  study  and 
  d u r i n g  t h e  m o n t h  b e f o r e  t h e  s t u d y
Immunosuppressive  therapy 
  H i g h  d o s e  s t e r o i d  ( n , % )
    Mean  cumulative  steroid  dose  (mg)
  C y c l o s p o r i n  ( n , % )
    Cyclophosphamide  (n,%)
  A z a t h i o p r i n e  ( n , % )
    Immunosuppresive  therapy  with  any  one  drug  or  more  (n,%)
32.5±11.5
5.2±4.0
40  (100.0)
30  (75.0)
26  (65.0)
26  (65.0)
18  (45.0)
10  (25.0)
8  (20.0)
12  (30.0)
8  (20.0)
2/8
4/8
2/8
10  (25.0)
4  (10.0)
3  (7.5)
0  (0.0)
0.7±0.3
1.3±1.3
10  (25.0)
6321.6±3798.1
10  (25.0)
3  (7.5)
7  (17.5)
24  (60.0)
Table  3.  Clinical  findings  in  the  patients  with  Behcet’s  disease
of  immunosuppressive  therapy  or  involvement  of  major  organs 
(Table 5). The  carotid IMT in the  20  patients  who were  treated 
with  a  cumulative  steroid  dose  >  6000  mg  did  not  significantly 
differ  from  that  in  the  20  patients  who  had  not  received  a 
cumulative  steroid  dose  ≤6000  mg  (0.70±0.18  mm  vs. 
0.73±0.19  mm,  respectively,  p=0.719;  the  mean  cumulative 
steroid  dose,  10357.8±4818.1  mg  vs.  2511.7±930.1  mg, 
respectively, p<0.001). On the multivariate analysis, the presence 
of posterior uveitis or retinal vasculitis was associated with a high 
carotid  IMT  (Table  6).
DISCUSSION
Acute  systemic  inflammation  and  chronic  systemic  vasculitis 
are  known  to  be  associated  with  ECD
7, 8).  Systemic  inflam-
matory rheumatic diseases such as RA and SLE are associated 
with  a  significantly  increased  risk  of  cardiovascular  disease, 
which  often  occurs  at  a  younger  age  for  these  patients  as 
compared  to  the  normal  population
5).  Vasculitis  also  plays  an 
important  role  in  atherogenesis
18),  a s  h a s  b e e n  s h o w n  f o r  
Takayasu  arteritis
19)  and  Wegener's  granulomatosis
20).  BD  is  a 
chronic, systemic inflammatory disorder with a diverse spectrum 
of  clinical  manifestations,  including  mucocutaneous,  ocular, 
vascular,  gastrointestinal,  musculoskeletal  and  central  nervous 
system  involvement
1).  Vascular  involvement  in  BD  is  usually 
recognized as an unclassified vasculitis, and it involves both the 
veins and arteries of all sizes
21, 22).  Endothelial  cell  injury  or their 
pathological  activation  is  the  characteristic  features  of  BD.  An 
endothelial  product,  von  Willebrand  factor,  was  elevated  in  BD 
patients and particularly in the patients with active BD
23). Despite 
the  uncertainty  concerning  the  pathogenic  mechanism  of  the 
vascular  lesions  in  BD  patients,  vascular  endothelial  dysfunction 
has been recognized to occur in BD and it is thought to play an 
important  role  in  the  vascular  lesions
10). 
In  this  study,  we  demonstrated  that  the  carotid  IMT  was 
significantly  higher  in  BD  patients  than  that  in  healthy  controls. 
The  previous  studies  demonstrated  that  the  carotid  IMT  was 
significantly  higher  in  BD  patients  than  that  in  the  healthy 
controls
17, 24, 25).  However,  the  authors  of  those  studies  did  not 
investigate  the  carotid  IMT  according  to  the  presence  of  the 
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Correlation  (r) p V a l u e
Age
Age  at  diagnosis
Disease  duration
Erythrocyte  sedimentation  rate
C-reactive  protein
Total  cholesterol
Triglyceride
High-density  lipoprotein  cholesterol
Low-density  lipoprotein  cholesterol
Lipoprotein  (a)
Homocysteine
Cumulative  steroid  dose
Disease  activity  score  at  the  time  of  study
0.462
0.297
0.249
-0.327
-0.184
-0.236
0.100
0.026
-0.339
-0.108
0.298
0.099
0.180
0.040
0.204
0.291
0.144
0.438
0.330
0.684
0.900
0.156
0.670
0.230
0.687
0.447
Table  4. C o r r e l a t i o n  b e t w e e n  t h e  c a r o t i d  i n t i m a - m e d i a  t h i c k n e s s  a n d  t h e   clinical  and  laboratory  variables  in  patients  with  Behcet’s  disease
IMT  with  clinical  findings  (mm) IMT  without  clinical  findings  (mm) p v a l u e
Immunosuppressive  therapy
Cumulative  steroid  dose 
>  6000  mg
Posterior  uveitis  or  retinal  vasculitis
Ileocecal  ulceration  with  bleeding
Vascular  involvement
Major  organ  involvement
0.71±0.15
0.70±0.18
0.85±0.21
0.76±0.35
0.70±0.11
0.68±0.10
0.70±0.22
0.73±0.19
0.64±0.10
0.71±0.17
0.71±0.18
0.71±0.18
0.106
0.719
0.007
0.724
0.933
0.731
Table  5.  Carotid  intima-media  thickness  (IMT)  in  the  patients  with  Behcet’s  disease  according  to  the  clinical  findings
Parameters Odds  Ratio 95%  CI p V a l u e
Posterior  uveitis  or  retinal  vasculitis
Cumulative  steroid  dose 
Immunosuppresive  therapy
5.262
1.023
0.603
1.234-18.808
0.078-13.388
0.043-8.443
0.034
0.986
0.707
Table  6.  Multiple  regression  analysis  for  the  co-factors  that  affect  the  carotid  intima-media  thickness
disease  manifestations.  Alan  et  al.
24)  reported  that  the  carotid 
IMT  was  significantly  higher  and  the  arterial  distensibility  was 
s i g n i f i c a n t l y  l o w e r  i n  p a t i e n t s  w i t h  B D  a s  c o m p a r e d  t o  t h e  
controls.  The  IMT  values  were  even  higher  in  BD  patients  with 
vascular  involvement  compared  to  those  without  vascular 
involvement
24).  However,  BD  patients  with  major  vascular 
involvement were included in that study, and no information was 
given  regarding  the  use  of  steroid,  the  smoking  status  and  the 
conventional risk factors of atherosclerosis. Rhee et al. reported 
on t he  I MT a nd a r t e r i a l  s t i f f ne s s  of  t he  c a r ot i d a r t e r y  i n Kor ean 
patients with BD
26) and they demonstrated that BD patients had 
significantly  increased  arterial  stiffness  in  all  the  regional  arterial 
segments
27). In that study
26), there were significant differences in 
the carotid arterial stiffness parameters between the BD patients 
and  the  control  subjects;  however,  the  carotid  IMT  of  the 
patients  with  BD  was  not  different  from  that  of  the  control 
group.  They  did  not  evaluate  the  influence  of  the  serologic 
markers and the clinical manifestation of BD on the carotid IMT. 
In our study, the carotid IMT was significantly higher in the BD 
patients  with  posterior  uveitis  or  retinal  vasculitis  than  that i n  
those  BD  patients  without  posterior  uveitis  or  retinal  vasculitis. 
There  were  no  significant  differences  of  the  IMT  in  the 
subgroups  of  BD  with  regard  to  the  presence  of  vascular 
involvement  and  other  severe  manifestations  such  as  major 
organ involvement and a history of immunosuppressive therapy. 
Major  vascular  involvements  were  not  detected  in  our  study 
group. Posterior uveitis or retinal vasculitis was the most frequent 
severe  manifestation  of  BD  and  this  recurred  frequently  in  our 
study  group.  Also,  carotid  plaque  was  detected  in  the  patient 
with  recurrent  posterior  uveitis. 
CRP is a powerful predictor of cardiovascular disease and this 
was independent of the serum lipid levels. An elevated CRP level 
is a very accurate marker of ECD
28). Our data failed to show a 
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CRP level. The absence of a significant association between the 
carotid IMT and the CRP level might be explained by our use a 
conventional CRP assay, rather than using a high-sensitivity CRP 
(hsCRP) assay. If we had used a hsCRP assay, we might have 
found a positive correlation. Alternatively, the serum CRP level as 
determined by conventional assay fluctuates in BD patients and 
the  median  of  the  serial  measurements  may  be  more  reliable 
than  a  single  measurement.
In this study, the carotid IMT in the BD patients was positively 
correlated  with  age,  but  it  was  not  correlated  with  the  disease 
duration and cumulative steroid dose. Additionally, we could not 
demonstrate  any  correlation  between  the  disease  activity  score 
and the carotid IMT in the BD patient group. BD is characterized 
by  remissions  and  exacerbations,  and  it  is  a  multisystemic 
inflammatory disorder. Each of the BD patients had different and 
various clinical manifestations. Most patients were in the inactive 
p e r i o d  a n d  t h e i r  C R P  a n d  E S R  v a l u e s  w e r e  w i t h i n  t h e  n o r m a l  
limits  at  the  time  of  the  study.  Severe  disease  manifestations 
appeared less frequently and so the disease activity score at the 
time  of  study  and  during  the  month  before  the  study  started 
w a s  l o w  i n  o u r  s t u d y  g r o u p .  F u r t h e r  s t u d i e s  o n  p a t i e n t s  w i t h  
higher  disease  activity  will  clarify  whether  the  disease  severity 
increases  the  risk  of  subclinical  atherosclerosis  in  patients  with 
BD.
In  conclusion,  the  BD  patients  without  significant  cardiovas-
cular  involvement  demonstrated  a  higher  carotid  IMT  compared 
with  the  healthy  control  subjects.  The  increased  arterial  wall 
thickness  was  independently  associated  with  the  disease 
duration  and  the disease  activity  score.  Our  data did  not show 
a  significant  association  between  the  carotid  IMT  and 
immunosuppressive therapy, including high dose steroid therapy 
for  BD.  These  results  suggest  that  BD  itself  may  lead  to  an 
increased carotid IMT, and this is possibly due to an increase in 
the  atherosclerotic  changes.
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